https://www.statcounter.com/counter/counter.js
Web Analytics
Home » Posts tagged with » Novartis
Gilead Sciences licenses three preclinical antiviral programs from Novartis

Gilead Sciences licenses three preclinical antiviral programs from Novartis

US biopharma company Gilead Sciences has licensed three preclinical antiviral programs, including investigational candidates having the potential to treat human rhinovirus, influenza and herpes viruses, from Swiss pharma company Novartis. As per the agreement, Gilead Sciences will get exclusive global rights for the development and commercialization of small molecules against three undisclosed targets. Novartis will […]

Novartis to acquire IFM Tre with eye on immunomodulatory drugs

Novartis acquisition of IFM Tre : Novartis has signed a deal worth up to $1.575 billion to acquire US biopharma company IFM Tre from IFM Therapeutics. Novartis acquisition of IFM Tre The acquisition of the US biopharma company, which was only launched last year, is expected to add certain immunomodulatory drugs to the Swiss pharma […]

Continue reading …
Novartis’ Mayzent approved by FDA for treatment of relapsing forms of MS

Mayzent FDA approval : The US Food and Drug Administration (FDA) has approved Swiss pharma company Novartis’ Mayzent (siponimod) for the treatment of relapsing forms of multiple sclerosis (MS) in adults. Mayzent FDA approval The latest FDA approved Novartis MS drug can now be used for the treatment of secondary progressive multiple sclerosis (SPMS) with […]

Continue reading …
Blackstone Life Sciences, Novartis launch Anthos Therapeutics

Blackstone Life Sciences, a private investment platform, has joined forces with Swiss drug maker Novartis to launch a new biopharma company called Anthos Therapeutics, which will focus on developing drugs for high-risk cardiovascular patients. Anthos Therapeutics, which will be headquartered in Cambridge, Massachusetts, is backed by a capital of $250 million from Blackstone Life Sciences. […]

Continue reading …
Novartis gets Egaten FDA approval for fascioliasis treatment

Pharma regulatory news : Novartis has secured Egaten FDA approval for fascioliasis treatment in patients, aged six years and older. Fascioliasis is a neglected tropical disease, commonly known as liver fluke infestation. The disease is said to affect millions of people across the world. Fascioliasis is caused by two species of parasitic flatworms – Fasciola […]

Continue reading …
Clinigen to buy US rights to Proleukin from Novartis

British pharma company Clinigen has agreed to buy the US rights to Proleukin (aldesleukin, human recombinant interleukin-2) from Swiss pharma company Novartis in an all-cash transaction that could be worth up to $210 million. Proleukin is an FDA approved drug for metastatic melanoma and metastatic renal cell carcinoma. Clinigen has agreed to make the payments […]

Continue reading …
Novartis proposes to acquire French CDMO CellforCure from LFB

Novartis has proposed to acquire French contract development and manufacturing organizations (French CDMO) CellforCure from LFB for an undisclosed price. CellforCure is engaged in producing cell and gene therapies across Europe. The deal proposed by Novartis includes the cell and gene manufacturing facility in Les Ulis near Paris and the related adjacent land. If the […]

Continue reading …
Novartis breast cancer drug Kisqali plus endocrine therapy extends PFS

Novartis breast cancer drug Kisqali (ribociclib) plus endocrine therapy has succeeded in extending progression-free survival (PFS) compared to only endocrine therapy in three phase 3 MONALEESA trials. The findings come from the Swiss pharma company’s release of data from subgroup analyses of the three pivotal trials in pre-, peri- and postmenopausal women, irrespective of the […]

Continue reading …
Novartis bags Gilenya EC approval for multiple sclerosis in young patients

Gilenya EC approval : The European Commission (EC) has expanded the approval of Novartis multiple sclerosis drug Gilenya (fingolimod) to include the treatment of both children and adolescents, in the age group 10-17 years. Expanded Gilenya EC approval The expanded Gilenya EC approval is for the treatment of relapsing-remitting forms of multiple sclerosis (RRMS). Novartis already […]

Continue reading …
Spark Therapeutics bags Luxturna EU approval for inherited retinal disease

Luxturna EU approval for inherited retinal disease : Pennsylvania-based Spark Therapeutics has bagged the European Commission’s (EC) approval for its gene therapy Luxturna (voretigene neparvovec) to treat a rare inherited type of vision loss in both children and adults. Luxturna EU approval for inherited retinal disease Luxturna, an adeno-associated viral (AAV) vector gene therapy has […]

Continue reading …
Page 1 of 212